CHANGE IN RATINGS

Cephalon ( CEPH) upgraded at CIBC: CEPH was upgraded to Outperform, CIBC said. $89 price target. Strong Fentora and Provigil sales should offset any weakness at Actiq.

Express Scripts ( ESRX) upgraded at JP Morgan: ESRX was upgraded from Neutral to Overweight, JP Morgan said. Initial 2007 guidance, due out tomorrow, could be a positive catalyst. Looking for 20% annual growth.

Ensco ( ESV) downgraded at Morgan Stanley: ESV was downgraded to Underweight, Morgan Stanley said. $58 price target. Valuation call. Estimates and target moving higher, because of continued strength in the international jack-up market.

Gannett ( GCI) upgraded at Merrill: GCI was upgraded from Neutral to Buy, Merrill Lynch said. $65 price target. Company will likely boost dividend in the near term, but also has other potential ways to increase shareholder value.

Grant Prideco ( GRP) upgraded at Morgan Stanley: GRP was upgraded to Overweight, Morgan Stanley. Estimates also raised, to reflect the improving natural gas market. $54 price target.

Plains Exploration ( PXP) downgraded at Morgan Stanley: PXP was downgraded to Equal-weight, Morgan Stanley said. $49 price target. Market is already beginning to price in Gulf of Mexico success and the potential for share buybacks.

RF Micro ( RFMD) upgraded at CIBC: RFMD was upgraded from Sector Perform to Outperform, CIBC said. $9 price target. Company to benefit from new NOK products as well as PS3 sales in 2007.

SanDisk ( SAND) downgraded at UBS: UBS said it is downgrading SNDK to Neutral from Buy based on likely 2006/2007 NAND oversupply. Lowered target price to $55 from $75.

Skyworks ( SWKS) downgraded at Weisel: SWKS was downgraded from Outperform to Peer Perform, Thomas Weisel said. MOT delaying orders, as it switches to EDGE technology. Competition also heating up for Samsung.

Todco ( THE) upgraded at Morgan Stanley: THE was upgraded to Overweight, Morgan Stanley said. $50 price target. Estimates also upped, as jack-up rates should soon recover in the Gulf of Mexico.

STOCK COMMENTS / EPS CHANGES

Agilent ( A) estimates lowered at Goldman: Goldman said it is reducing its 2007 estimates on A by 20 cents to $1.85 to account for Verigy distribution. Semiconductor test business distributed as special dividend to shareholders. Maintain Neutral rating and $35 target.

Bristol-Myers ( BMY) estimates cut at Morgan Stanley: BMY estimates lowered through 2007, Morgan Stanley said. Company meeting did not improve outlook for Plavix. Equal-weight rating and $25 price target.

Luminent ( LUM) outlook lowered at UBS: UBS said it is reduced its 2006 EPS estimates on LUM to $1.07 from $1.90 to reflect lower origination. Lowered target price to $11.50 from $12.

SiRF ( SIRF) estimates raised at Piper: Piper said it is raising its 2007 estimates on SIRF by 4 cents to $1.10 a share based on growing comfort with company's longer-term growth opportunities. Maintained Outperform rating.

More from Stocks

Dow Fluctuates, Nasdaq Strikes Record High

Dow Fluctuates, Nasdaq Strikes Record High

GE's Exit From Dow Could Be a Blessing in Disguise, Goldman Says

GE's Exit From Dow Could Be a Blessing in Disguise, Goldman Says

Own Retail Stocks? This Chart Will Make You Want to Instantly Cash Out

Own Retail Stocks? This Chart Will Make You Want to Instantly Cash Out

Disney CEO Bob Iger Touts Benefits of His Firm's Deal for Fox Beyond Just Money

Disney CEO Bob Iger Touts Benefits of His Firm's Deal for Fox Beyond Just Money

2 Things Fed Chairman Jerome Powell Just Said Upset Investors

2 Things Fed Chairman Jerome Powell Just Said Upset Investors